publication date: Jul. 6, 2018
Drugs & Targets FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients
FDA has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
The agency took action in June in response to decreased survival associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy compared to platinum-based chemotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1.
The labels of both drugs have been revised to reflect the limitation in the indication. The indications read as follows:
Keytruda is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing therapy and whose tumors express PD-L1 (Combined Positive Score ≥ 10), or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.
Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
Are not eligible for cisplatin-containing therapy, and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells covering ≥5% of the tumor area), as determined by an FDA-approved test, or
Are not eligible for any … Continue reading FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.